The Parkinsonís Institute and Clinical Center and Denali Therapeutics announced a partnership to explore endpoints studies of patients with Parkinsonís Disease.
 
Published Monday, March 19, 2018 12:00 pm
by Joy Chesbrough

The Institute and Denali aim to support the development of new PD therapeutics by better understanding the potential of new endpoints for clinical studies. Known clinical endpoints for PD can be affected by current standard treatments which, in turn, may confound the measurement of new therapeutics’ impact.

The agreement brings together the unique expertise of the Institute and its broad patient experience with Denali as it continues the development of its LRRK2 inhibitor clinical program for Parkinson’s Disease. 

Read More


For Immediate Release: March 5, 2018
Contact: Joy Chesbrough (408) 542-5606
Contact: Chris Di Salvo  (408) 506-0455


Send this page to a friend

Show Other Stories

675 Almanor Avenue | Sunnyvale, CA 94085
408.734.2800 main | 408.734.8455 fax (Main) | 408.734.9208 fax (Clinic Secure)